Ventriculostomy-Related Infections by Country-Income Level: A Systematic Review and Bayesian Hierarchical Meta-analysis.

J Neurosurg AnesthesiolJun 15, 2026 (epub)
Clinical ResearchNeurosurgery

Samuel N Blacker, Hemanshu Prabhakar, Elizabeth Olive Moreton et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and Bayesian hierarchical meta-analysis evaluated ventriculostomy-related infection (VRI) rates in adults across different country-income levels. Analyzing 159 articles with 523,704 patients, the pooled VRI rate was found to be 8.64% (95% CI: 7.44-9.97). The study highlights significant variations in VRI rates based on definitions used and geographic location.

Key findings

  • The pooled VRI rate was 8.64% with moderate heterogeneity.
  • VRI rates were significantly higher in studies using definitions beyond CSF culture alone (+3.16%).
  • European studies reported a VRI increase of +7.29% compared to other regions.
  • Only five of the 33 countries had VRI rates below the global pooled rate.

Why it matters

Understanding VRI rates and their variations by income level and definition is crucial for clinicians to benchmark and improve infection control practices in neurosurgery.

Source

PubMed · PMID 42290525

Published in J Neurosurg Anesthesiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.